Kamada Ltd. (NASDAQ:KMDA – Get Free Report) announced a special dividend on Saturday, November 7th. Shareholders of record on Thursday, November 19th will be given a dividend of $0.14 per share by the biotechnology company on Wednesday, December 9th. The ex-dividend date is Thursday, November 19th.
Kamada has a dividend payout ratio of 30.8% indicating that its dividend is sufficiently covered by earnings. Research analysts expect Kamada to earn $0.58 per share next year, which means the company should continue to be able to cover its $0.12 annual dividend with an expected future payout ratio of 20.7%.
Kamada Stock Up 6.6%
Shares of NASDAQ:KMDA traded up $0.48 during midday trading on Monday, hitting $7.71. 171,844 shares of the stock traded hands, compared to its average volume of 82,330. The stock has a market capitalization of $443.36 million, a PE ratio of 20.29, a P/E/G ratio of 0.61 and a beta of 0.90. The business’s 50 day moving average is $8.08 and its two-hundred day moving average is $8.00. Kamada has a one year low of $6.59 and a one year high of $9.35.
Kamada (NASDAQ:KMDA – Get Free Report) last issued its quarterly earnings data on Monday, November 9th. The biotechnology company reported $0.14 EPS for the quarter, topping the consensus estimate of $0.13 by $0.01. The business had revenue of $52.03 million during the quarter, compared to analyst estimates of $52.51 million. Kamada had a net margin of 11.60% and a return on equity of 8.37%. As a group, sell-side analysts forecast that Kamada will post 0.48 earnings per share for the current year.
More Kamada News
Here are the key news stories impacting Kamada this week:
- Positive Sentiment: Kamada reported record results for the first nine months of 2026, raised its full-year revenue guidance to $205 million–$208 million and projected double-digit revenue and profitability growth in 2027. Company results and outlook
- Positive Sentiment: The company secured a three-year, $50 million U.S. source-plasma supply deal. Its Q3 gross margin was reported at 45%, with sales growth in key products and distribution revenue also supporting the outlook. Plasma deal and growth report
- Positive Sentiment: Q3 earnings were $0.14 per share, beating the $0.13 consensus and rising from $0.09 a year earlier. Stifel also raised its price target to $12. Earnings estimate comparison Stifel price-target update
- Positive Sentiment: Kamada declared a special cash dividend of $0.14 per share, adding a direct shareholder return. Dividend announcement
- Negative Sentiment: Quarterly revenue was $52.03 million, just below analysts’ $52.51 million estimate, tempering the earnings beat.
About Kamada
Kamada Ltd. is a biopharmaceutical company focused on the development, manufacturing and commercialization of plasma-derived therapeutics and specialty pharmaceutical products. The company uses its expertise in plasma protein purification to address rare diseases, immune deficiencies and other serious medical conditions.
Kamada’s portfolio includes GLASSIA, an intravenous alpha-1 antitrypsin therapy used as augmentation treatment for adults with severe alpha-1 antitrypsin deficiency and emphysema.
See Also
- Five stocks we like better than Kamada
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for Kamada Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada and related companies with MarketBeat.com's FREE daily email newsletter.
